About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to ...
Feb 26, 2015
0
8
A promising method of immunotherapy to treat children with relapsed acute lymphocytic leukemia (ALL) is opening at the University of Wisconsin Carbone Cancer Center and American Family Children's Hospital. The trial is open ...
Feb 25, 2015
0
14
Scientists from the CNRS, INSERM and Université de Limoges, working in the Laboratoire Contrôle de la Réponse Immune B et Lymphoproliférations (CNRS/Université de Limoges) have demonstrated that the production of type ...
Feb 13, 2015
0
7
The genetic variability of a tumour could be a predictor for its aggressiveness: the greater the variability in gene expression, the more aggressive the tumour is likely to be. This is the hypothesis that the CNIO Structural ...
Feb 5, 2015
1
9
Dendritic cells and macrophages are immune cells that orchestrate diverse immune functions within many body tissues, including the skin. New work by A*STAR researchers and colleagues shows that CD14+ cells in the skin—long ...
Feb 4, 2015
0
8
How can our immune system defend us against aggressors so diverse such as viruses, parasites, fungi and tumours? The secret lies in the large number of clones of T and B lymphocytes, each of which expresses a particular specific ...
Jan 23, 2015
0
9
The American Society of Clinical Oncology (ASCO) for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic ...
Jan 20, 2015
0
38
Idelalisib (trade name Zydelig) has been available since September 2014 for patients with follicular lymphoma or chronic lymphocytic leukaemia (CLL). The German Institute for Quality and Efficiency in Health Care (IQWiG) ...
Jan 8, 2015
0
3
The latest results of clinical trials of more than 125 patients testing an investigational personalized cellular therapy known as CTL019 will be presented by a University of Pennsylvania research team at the 56th American ...
Dec 8, 2014
0
0
A new study published in the scientific journal Proceedings of the National Academy of Sciences(PNAS) sheds new light on a well-known mechanism required for the immune response. Researchers at the IRCM, led by Tarik Möröy, ...
Dec 5, 2014
0
0
